NEWS

Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership

Fibronostics US INC, receives CE (Conformité Européenne) mark approval for the product LIVERFASt™

AASLD Poster: LIVERFASt is detecting and discriminant different phases of liver disease, with better performances than APRI or FIB-4.

Fatty Liver Foundation featuring LIVERFASt™.

AASLD Poster: Comparative performance of LIVERFASt™, Fibroscan and other non-invasive test for Severe Fibrosis in NAFLD Patients.

Non-Invasive testing for NASH at the AASLD Liver Meeting.

LIVERFASt™ provides the right diagnosis of liver disease conditions in type 2 diabetes patients.

Fibronostics on its way to be a Healthcare Technology Powerhouse – Raises $8 Million Series A funding.

Fibronostic’s Chief Scientific Officer,Dr Mona Munteanu, discussed relevance of Non-Invasive Testing for HCC Surveillance in global Webinar series.

Sought-after Hepatology and Gastroenterology expert, Prof. Stephen A. Harrison MD joins Fibronostics’ Advisory Board.

LIVERFASt screening and diagnostics capabilities combines with Health Catalyst National Registry power up a COVID19 study.

Know the advantages of non-invasive liver diagnostics over standard biopsy as explained by our CEO, Roni Amiel.

Celebrating a major milestone! Fibronostics granted CPT code for LIVERFASt, our non-invasive liver diagnostics tool.

When things go tough due to flight restrictions, we conduct our CMEs through video conferences by our Chief Medical Officer, Dr Ronald Quiambao.

Fibronostics presented a Scientific poster “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt™ test in South-East Asia”.at the NASH-TAG 2020, UTAH for.

AC Health announces Investment in Fibronostics by launching LIVERFASt and HealthFACTR in its FamilyDOC Clinics.

Fibronostics presented our corporate strategy to current & potential investors in TKS 1 Investor Day in Singapore.

Fibronostics mingles with industry leaders during inspiring few days at the American Association for the Study of Liver Diseases (AASLD) #LiverMtg19.

Fibronostics is proud to partner with the CXA Group offering health and wellness screenings with HealthFACTR.